Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vir Biotechnology Inc. Common Stock (VIR) vs Virtu Financial Inc. Class A Common Stock (VIRT) Price & Performance

Vir Biotechnology Inc. Common StockTrade
Virtu Financial Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Vir Biotechnology Inc. Common Stock vs Virtu Financial Inc. Class A Common Stock — how do they compare? Vir Biotechnology Inc. Common Stock trades at $10.41 (market cap $1.76B), while Virtu Financial Inc. Class A Common Stock trades at $57.67 (market cap $4.94B). The key difference: Virtu Financial Inc. Class A Common Stock is far larger — about 2.8× Vir Biotechnology Inc. Common Stock's market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.72% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vir Biotechnology Inc. Common Stock for 0 Days and Virtu Financial Inc. Class A Common Stock for 6 Days on average.

VIRVIRT
Market Cap
$1.76B$4.94B
Volume
2,764,9481,546,091
Sector
HealthFinancials
52-Week High
$11.78$67.93
52-Week Low
$5.12$32.53
Typical Hold Time
0 Days6 Days
Enterprise Value
$1.32B$14.65B
Dividend Yield
—1.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Virtu Financial Inc. Class A Common Stock

VIRT trades at $55.94, down 1.46% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.29, net income margin of 13.5%, and ROE of 31.65%. Recent expansion into Saudi Exchange block trading and consistent earnings outperformance support growth prospects. Analyst consensus price target is $63.00 with mixed ratings (38% buy, 46% hold).

VIRT presents a value opportunity with attractive valuation metrics and strong profitability, though technical indicators suggest near-term pressure. The company's market-making business demonstrates resilience with improving cash flow trends. Key risks include market volatility sensitivity and competitive pressures in financial services.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VIR
51% Buy49% Sell
Avg holding period · 0 Days
VIRT

No sentiment data available yet.

Top news

Latest headlines on both assets

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →

About Virtu Financial Inc. Class A Common Stock

Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.

Read more on VIRT →